Clinical trials: Light Chain Amyloidosis
Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
The study will provide information on outcomes in people with multiple myeloma, or systemic AL amyloidosis, or both, under standard care. AL is short for amyloid light-chain.
- Trial name
- DOrianT (NCT04659798)
- Where
- 14 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Takeda
AL Amyloidosis
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response. This is a single-arm, multi-center, prospective study.
- Trial name
- NCT06699394
- Testing
- Teclistamab (Tec)
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Amyloidosis
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Amyloidosis results from tissue deposition of amyloid protein, composed mainly by the fragments of monoclonal immunoglobulin heavy chains or light chains.
- Trial name
- NCT00621400
- Testing
- Lenalidomide, Melphalan, Dexamethasone
- Where
- 12 sites in France
- Volunteers
- 27 people
- Sponsor
- Nantes University Hospital
Amyloidosis
Safety and Effect of Doxycycline in Patients With Amyloidosis
The tetracycline antibiotic doxycycline disrupts A beta amyloid fibrils (AB) in Alzheimer's disease, transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and immunoglobulin light chain (AL) amyloid fibrils…
- Trial name
- NCT01677286
- Testing
- Doxycycline 100 mg po bid x 12 months
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Boston University
Systemic Light Chain Amyloidosis
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
This study is a clinical trial aimed at the marketing of TQB2934 for injection. The project plans to enroll 70 subjects, including 13-21 subjects in Phase Ib, to evaluate the safety and preliminary efficacy, pharmacokinetic (PK)…
- Trial name
- NCT07266116
- Testing
- TQB2934 injection
- Where
- 27 sites in China
- Volunteers
- 70 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
AL Amyloidosis
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
This is a multicenter open-label, phase 2 study in participant with previously treated immunoglobulin light-chain (AL) Amyloidosis to evaluate the benefit of teclistamab
- Trial name
- NCT06649695
- Testing
- Teclistamab
- Where
- 9 sites in Australia, France and 4 more
- Volunteers
- 30 people
- Sponsor
- European Myeloma Network B.V.
Chronic Myeloproliferative Disorders, Leukemia
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006348
- Testing
- ondansetron
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma, AL Amyloidosis
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
The goal of this clinical trial is to learn if teclistamab in combination with daratumumab (Tec-Dara) works to treat newly diagnosed multiple myeloma with concurrent light chain amyloidosis (MM+AL).
- Trial name
- NCT07638683
- Testing
- Teclistamab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Primary Amyloidosis of Light Chain Type
High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.
- Trial name
- DIACAL (NCT01531751)
- Testing
- High Cut-off Hemodialysis, Chemotherapy
- Where
- Italy
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer.
- Conditions
- Chronic Myeloproliferative Disorders, Fever, Sweats, and Hot Flashes, Infection, Leukemia
- Trial name
- NCT00062231
- Testing
- amoxicillin-clavulanate potassium, ciprofloxacin, moxifloxacin hydrochloride
- Where
- 23 sites in Belgium, France and 6 more
- Volunteers
- 351 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: High-dose chemotherapy may destroy the amyloid-producing cells in bone marrow. Peripheral stem cell transplantation PURPOSE: Phase II trial to study the effectiveness of high dose melphalan plus peripheral stem cell…
- Trial name
- NCT00003353
- Testing
- filgrastim, melphalan, bone marrow ablation with stem cell support
- Where
- 17 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Light-Chain Amyloidosis
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated…
- Trial name
- NCT01318902
- Testing
- Ixazomib, Dexamethasone
- Where
- 10 sites in United States, Canada and 3 more
- Volunteers
- 27 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Light Chain Cardiac Amyloidosis
CAR-NK Therapy for Cardiac Amyloidosis
Relapsed/refractory (R/R) light chain cardiac amyloidosis is associated with a poor prognosis, and cellular immunotherapy constitutes a crucial therapeutic modality for these patients.
- Trial name
- NCT07504289
- Testing
- CAR-NK
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Amyloid Cardiomyopathy, Congestive Heart Failure
Longitudinal Changes in Left and Right Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
The purpose of this study to assess the longitudinal changes in left and right ventricular global strain after chemotherapeutic strategies in cardiac light chain amyloidosis.
- Conditions
- Amyloid Cardiomyopathy, Congestive Heart Failure, Chemotherapy Effect
- Trial name
- NCT05452850
- Testing
- Left and Right Ventricular Global Strain Imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Light Chain Cardiac Amyloidosis
Beta-amyloid PET/CT to Measure Potential Therapeutic Response in AL-CA
This was a single center, prospective cohort study that is evaluating the ability of beta-amyloid dynamic PET/CT to detect potential therapeutic changes in subjects under treatment for AL-CA after one year had elapsed since their…
- Trial name
- Abeta-MTRALCA (NCT07829705)
- Testing
- 11C-PIB, 18F-Florbetapir
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
AL Amyloidosis, MGUS
Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment
Immunoglobulin light chain (AL) amyloidosis is caused by a typically small, minimally proliferating bone marrow plasma cell clone secreting a patient-unique, unstable, aggregation-prone, toxic light chain (LC).
- Conditions
- AL Amyloidosis, MGUS, Multiple Myeloma, Monoclonal Gammopathies
- Trial name
- GlycAL (NCT07448779)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Amyloid, Amyloidosis
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.
- Conditions
- Amyloid, Amyloidosis, AL Amyloidosis
- Trial name
- STARR (NCT04984330)
- Testing
- Selinexor, Dexamethasone
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University